hep-c-action-day-fb-bannerAccording to the CDC, July 25th is the third annual National African American Hepatitis C Action Day (NAAHCA). On this day, CDC and its public health partners will join the National Black Leadership Commission on AIDS, Inc. (NBLCA) to help promote the day in an effort to educate African Americans about the seriousness of Hepatitis C.  

Five facts you should know about Hepatitis C.

  1. Hepatitis C is a leading cause of liver cancer.
  2. Hepatitis C is a blood-borne virus.
  3. Hepatitis C testing is not part of routine blood work.
  4. Millions of Americans have hepatitis C, but most don’t know it because there are often no symptoms.
  5. Black people have a much higher risk of infection. Talk to your doctor or nurse practitioner. Early detection can save lives. The National Black Leadership Commission on AIDS and the Coalition for Positive Health Empowerment urge you to get tested, get treated, and get the word out. Visit [website] for more information.

According to the CDC – Persons for Whom Routine HCV Testing Is of Uncertain Need

  • Recipients of transplanted tissue (e.g., corneal, musculoskeletal, skin, ova, sperm)
  • Intranasal cocaine and other non-injecting illegal drug users
  • Persons with a history of tattooing or body piercing
  • Persons with a history of multiple sex partners or sexually transmitted diseases
  • Long-term steady sex partners of HCV-positive persons

According to the CDC – Persons for Whom Routine HCV Testing Is Not Recommended (unless they have risk factors for infection):

  • Health-care, emergency medical, and public safety workers
  • Pregnant women
  • Household (nonsexual) contacts of HCV-positive persons
  • General population

Treatment options according to the American Association For The Study of Liver Disease – HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C

An Unforeseen Complication of the New Hepatitis C Drugs

Hepatitis B might flare during treatment for hepatitis C.

Effective and nontoxic new drugs for eradicating hepatitis C virus (HCV) have inspired a well-deserved wave of enthusiasm among clinicians. However, an intriguing pair of case reports suggests these drugs should be used with caution in HCV-positive patients who also are infected with hepatitis B virus (HBV). These two patients, HIV-negative men in their mid-50s, had chronic HBV and HCV genotype 1a infections; HCV treatment with peginterferon plus ribavirin had failed.

One patient had barely detectable HBV DNA (2300 IU/mL) at the beginning HCV treatment with sofosbuvir (Sovaldi) and simeprevir (Olysio). By week 4 after the start of treatment, HCV viral load was undetectable. At week 7, jaundice, abdominal pain, and other evidence of severe viral hepatitis developed; HCV RNA remained undetectable, but HBV DNA was 22 million IU/mL. HCV treatment was stopped, and HBV treatment with combination tenofovir and emtricitabine was begun. At week 28, the patient was well, and neither virus was detectable in his blood.

In the other patient, HBV viral load was monitored from the outset of treatment with sofosbuvir and simeprevir. HBV DNA was undetectable prior to treatment but rose to 11,255 IU/mL by week 4. Although the patient remained asymptomatic, tenofovir was added to the treatment regimen, and both viruses were undetectable at week 12.

 

#HepatitisC #HCVTreatment #HepatitisB #HepatitisBTreatment #NursePractitioner #MedicalProvider #NPLeader #MooreOnHealth

– See more at: http://www.jwatch.org/na39275/2015/10/08/unforeseen-complication-new-hepatitis-c-drugs?ijkey=w7CHfu7thGeSQ&keytype=ref&siteid=jwatch&query=pfw-featured&variant=full-text#sthash.t7QxCDn5.dpuf

Moore On Health with Dru at SBNCHepatitis C is a rapidly evolving area that has recently gotten significant attention in the press as well as among scientists and medical experts. Seen here in this photo are two members from of the Santa Barbara Neighborhood Clinics Hepatitis C multidisciplinary team reviewing the DHCS Treatment Policy.

#HepatitisC #HCVTeam #NursePractitioner

For more information about this treatment policy go to http://www.dhcs.ca.gov/Pages/HepatitisC.aspx